Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zonisamide Oral Suspension in Children With Partial-onset Seizures
NCT06534502Phase 4Not yet recruiting
- Sponsor
- Azurity Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of zonisamide in focal onset seizure, sponsored by Azurity Pharmaceuticals. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
zonisamide
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT06534502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06534502.